by Stacey Hawkins | Jan 6, 2020 | Groundbreaking New Therapies in Development
Proteasomes to the Rescue Many drugs work by stopping overactive proteins that cause disease. The leukemia drug Gleevec, for example, is a small-molecule inhibitor (antagonist) of the protein Bcr-Abl, whose overactivity promotes excessive cell division. Humira... 
by Stacey Hawkins | Sep 14, 2017 | Oncology
BLOOD CANCER: MULTIPLE MYELOMA Plasma cells are the antibody-producing cells of our immune system which happen to play a critical role in our defense against infections. In multiple myeloma, plasma cells begin to grow and divide in an uncontrolled manner, forming a... 
by Stacey Hawkins | Mar 17, 2016 | Uncategorized
Alzheimer’s Pipeline Roundup Alzheimer’s disease ranks as one of the toughest nuts to crack within drug discovery and development. Current treatments merely manage symptoms, so finding a better solution becomes more and more urgent as the aging population grows.... 
by Stacey Hawkins | Feb 4, 2016 | Uncategorized
Antagonists Fight A Good Fight Small molecule inhibitors, also known as antagonists in the industry, fight a good fight. In fact, many drugs on the market today work by inhibiting overactive, disease-associated proteins. Novartis’ (Basel, Switzerland) top...
